Soc. Generale Discount Zert COP 2.../ DE000SV9BUW3 /
2024-05-31 9:37:38 PM | Chg.+0.290 | Bid9:59:38 PM | Ask9:59:38 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
27.510EUR | +1.07% | 27.600 Bid Size: 400 |
27.820 Ask Size: 400 |
COMPUGROUP MED. NA O... | - - | 2024-06-28 | Call |
GlobeNewswire
9:00 PM
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
GlobeNewswire
7:39 PM
QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 ...
GlobeNewswire
7:02 PM
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
4:00 PM
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstr...
GlobeNewswire
4:00 PM
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Gli...
GlobeNewswire
4:00 PM
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
3:14 PM
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
GlobeNewswire
3:00 PM
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Ther...
GlobeNewswire
3:00 PM
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
2:15 PM
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with ...
GlobeNewswire
2:15 PM
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
GlobeNewswire
2:05 PM
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting